← All trials
NCT03521973
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2018
- Primary completion
- Oct 31, 2019
- Completion date
- Apr 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanaria Inc.Lead sponsor
- Centre de Recherches Médicales de LambarénéOverall official - principal investigator
- Centre de Recherches Médicales de LambarénéCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.